An Implantable Wireless Interstitial Pressure Sensor With Integrated Guyton Chamber: in vivo Study in Solid Tumors

A wireless implantable interstitial fluid pressure (IFP) sensor with an integrated Guyton chamber is presented. This implantable device enables noninvasive and continuous measurements of IFP. The Guyton chamber allows for an accurate measurement of IFP without the interference from various cellular/tissue components. The sensor consists of a coil, an air chamber, a silicone membrane embedded with a nickel plate, and a Guyton chamber. The fabricated device is 3 mm in diameter and 1 mm in thickness. The sensor shows a linear response to the pressure with a sensitivity of 60 kHz/mmHg and a resolution of 1 mmHg. Experiments in human prostate cancer tumors grown in mice confirm the sensor's capability to operate in vivo and provide continuous wireless measurement of IFP, a surrogate parameter indicating the “window of opportunity” for delivering chemo- and radio-therapeutic agents.

[1]  B. Ziaie,et al.  A wireless interstitial pressure sensor with a Guyton chamber , 2013, 2013 Transducers & Eurosensors XXVII: The 17th International Conference on Solid-State Sensors, Actuators and Microsystems (TRANSDUCERS & EUROSENSORS XXVII).

[2]  Ugur Ozerdem,et al.  Measuring interstitial fluid pressure with fiberoptic pressure transducers. , 2009, Microvascular research.

[3]  R. Reed,et al.  Rat brain interstitial fluid pressure measured with micropipettes. , 1983, The American journal of physiology.

[4]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.

[5]  W. Sessa,et al.  Antiangiogenic therapy: creating a unique "window" of opportunity. , 2004, Cancer cell.

[6]  P. Gullino,et al.  THE INTERSTITIAL FLUID OF SOLID TUMORS. , 1964, Cancer research.

[7]  A C Guyton,et al.  Interstitial Fluid Pressure , 1968, Circulation research.

[8]  M Beth McCarville,et al.  Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy , 2007, Clinical Cancer Research.

[9]  Barbara Sennino,et al.  Controlling escape from angiogenesis inhibitors , 2012, Nature Reviews Cancer.

[10]  B. Ziaie,et al.  A batch fabricated capacitive pressure sensor with an integrated Guyton capsule for interstitial fluid pressure measurement , 2011 .

[11]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[12]  R. Reed,et al.  Micropuncture measurement of interstitial fluid pressure in rat subcutis and skeletal muscle: comparison to wick-in-needle technique. , 1981, Microvascular research.

[13]  Kristian Pietras,et al.  High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.

[14]  Rakesh K. Jain,et al.  Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.

[15]  Ricky T. Tong,et al.  Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. , 2007, Cancer research.

[16]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[17]  N. Andratschke,et al.  Current status of angiogenesis inhibitors combined with radiation therapy. , 2006, Cancer treatment reviews.

[18]  Dai Fukumura,et al.  Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize , 2007, Journal of cellular biochemistry.

[19]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[20]  A. Guyton,et al.  A Concept of Negative Interstitial Pressure Based on Pressures in Implanted Perforated Capsules , 1963, Circulation research.

[21]  P. Iversen,et al.  Interstitial fluid: the overlooked component of the tumor microenvironment? , 2010, Fibrogenesis & tissue repair.

[22]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[23]  Kristina M. Cook,et al.  Angiogenesis Inhibitors: Current Strategies and Future Prospects , 2010, CA: a cancer journal for clinicians.

[24]  Peter Carmeliet,et al.  Angiogenesis in life, disease and medicine , 2005, Nature.